Rezolute Inc Financials

RZLT

Source SEC Filings (10-K/10-Q) Updated Feb 12, 2026 Currency USD FYE June

This page shows Rezolute Inc (RZLT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Rezolute Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.93x

For every $1 of reported earnings, Rezolute Inc generates $0.93 in operating cash flow (-$69.1M OCF vs -$74.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$79.9M

YoY-13.5%

Rezolute Inc's EBITDA was -$79.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 13.5% from the prior year.

Free Cash Flow

N/A

Net Income

-$74.4M

YoY-8.7%

Rezolute Inc reported -$74.4M in net income in fiscal year 2025. This represents a decrease of 8.7% from the prior year.

EPS (Diluted)

$-0.98

YoY+26.3%

Rezolute Inc earned $-0.98 per diluted share (EPS) in fiscal year 2025. This represents an increase of 26.3% from the prior year.

Cash & Debt

$94.1M

YoY+33.7%

5Y CAGR+4.0%

10Y CAGR+33.4%

Rezolute Inc held $94.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

87M

YoY+63.4%

Rezolute Inc had 87M shares outstanding in fiscal year 2025. This represents an increase of 63.4% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$61.5M

YoY+10.4%

5Y CAGR+33.6%

10Y CAGR+29.3%

Rezolute Inc invested $61.5M in research and development in fiscal year 2025. This represents an increase of 10.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RZLT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$61.5M+10.4%	$55.7M+27.2%	$43.8M+34.9%	$32.5M+116.8%	$15.0M+3.7%	$14.4M
SG&A Expenses	$18.4M+25.1%	$14.7M+20.6%	$12.2M+30.1%	$9.4M+18.3%	$7.9M+30.2%	$6.1M
Operating Income	-$79.9M-13.4%	-$70.4M-25.8%	-$56.0M-33.8%	-$41.8M-82.8%	-$22.9M-11.6%	-$20.5M
Interest Expense	N/A	N/A	N/A	N/A	$375K	$0
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$74.4M-8.7%	-$68.5M-32.2%	-$51.8M-26.1%	-$41.1M-96.4%	-$20.9M-2.8%	-$20.3M
EPS (Diluted)	$-0.98+26.3%	$-1.33-31.7%	$-1.01+56.5%	$-2.32	$-2.72	N/A

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$14K-99.9%	$14.3M+9.1%	$13.1M-14.0%	$15.3M+21.0%	$12.6M-1.0%	$12.8M+2.8%	$12.4M+3.0%	$12.0M
SG&A Expenses	$10K-99.9%	$9.9M+48.1%	$6.7M+40.7%	$4.7M+6.4%	$4.5M+6.4%	$4.2M+9.8%	$3.8M+20.8%	$3.2M
Operating Income	$24K+100.1%	-$24.2M-22.2%	-$19.8M+1.0%	-$20.0M-17.2%	-$17.1M-0.8%	-$16.9M-4.5%	-$16.2M-6.7%	-$15.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	$23K+100.1%	-$22.8M-25.5%	-$18.1M+4.0%	-$18.9M-20.2%	-$15.7M-2.3%	-$15.4M+9.8%	-$17.1M-22.6%	-$13.9M
EPS (Diluted)	$0.22+200.0%	$-0.22-22.2%	$-0.18+33.3%	$-0.27-22.7%	$-0.220.0%	$-0.22+35.3%	$-0.34-25.9%	$-0.27

RZLT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$175.5M+32.2%	$132.7M+7.3%	$123.7M-18.8%	$152.4M+257.7%	$42.6M+288.6%	$11.0M
Current Assets	$171.1M+33.0%	$128.7M+22.6%	$104.9M-31.0%	$152.1M+262.2%	$42.0M+299.2%	$10.5M
Cash & Equivalents	$94.1M+33.7%	$70.4M+339.0%	$16.0M-89.3%	$150.4M+266.4%	$41.0M-47.0%	$77.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.4M+13.9%	$11.7M+55.4%	$7.5M+156.0%	$2.9M-82.1%	$16.5M+358.6%	$3.6M
Current Liabilities	$11.9M+24.0%	$9.6M+84.7%	$5.2M+111.2%	$2.5M+25.1%	$2.0M-39.0%	$3.2M
Long-Term Debt	N/A	N/A	N/A	N/A	$14.0M	$0
Total Equity	$162.1M+34.0%	$121.0M+4.2%	$116.2M-22.3%	$149.5M+472.7%	$26.1M+254.4%	$7.4M
Retained Earnings	-$403.9M-22.6%	-$329.4M-26.2%	-$261.0M-24.8%	-$209.2M-24.4%	-$168.1M-14.2%	-$147.2M

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Total Assets	$139K-99.9%	$138.6M-12.6%	$158.7M+67.5%	$94.7M-15.4%	$112.0M-9.2%	$123.4M+40.7%	$87.7M-14.1%	$102.2M
Current Assets	$135K-99.9%	$135.1M-12.7%	$154.7M+74.3%	$88.7M-10.1%	$98.7M-10.4%	$110.2M+34.0%	$82.2M-14.4%	$96.1M
Cash & Equivalents	$12K-99.9%	$11.9M+31.3%	$9.1M-37.7%	$14.6M+63.4%	$8.9M-14.7%	$10.5M+76.6%	$5.9M-52.6%	$12.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11K-99.9%	$10.6M-7.5%	$11.5M-5.5%	$12.2M-2.0%	$12.4M+24.5%	$10.0M-40.9%	$16.9M+61.9%	$10.4M
Current Liabilities	$10K-99.9%	$9.5M-6.7%	$10.2M-3.0%	$10.5M-0.8%	$10.6M+32.7%	$8.0M+14.9%	$7.0M-13.1%	$8.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$128K-99.9%	$128.0M-13.0%	$147.2M+78.2%	$82.6M-17.1%	$99.6M-12.2%	$113.4M+60.1%	$70.9M-22.7%	$91.7M
Retained Earnings	$445K+100.1%	-$444.8M-5.4%	-$422.0M-11.2%	-$379.5M-5.2%	-$360.6M-4.6%	-$344.8M-12.5%	-$306.5M-5.9%	-$289.4M

RZLT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$69.1M-20.5%	-$57.4M-29.0%	-$44.5M-12.3%	-$39.6M-93.8%	-$20.4M+15.4%	-$24.2M
Capital Expenditures	N/A	N/A	$153K	N/A	N/A	$0
Free Cash Flow	N/A	N/A	-$44.6M	N/A	N/A	-$24.2M
Investing Cash Flow	-$14.5M-129.9%	$48.7M+148.0%	-$101.5M	N/A	$0	$0
Financing Cash Flow	$107.3M+70.3%	$63.0M+444.7%	$11.6M-92.2%	$149.0M+189.1%	$51.5M+128.5%	$22.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$3K	N/A	N/A	N/A	N/A

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Operating Cash Flow	$38K+100.2%	-$20.3M-16.6%	-$17.4M-0.2%	-$17.4M-27.3%	-$13.7M+14.7%	-$16.0M-5.1%	-$15.2M-17.1%	-$13.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$11.3M
Investing Cash Flow	$46K-99.8%	$22.8M+133.3%	-$68.5M-397.1%	$23.1M+101.0%	$11.5M+123.2%	-$49.4M-669.9%	$8.7M-51.2%	$17.8M
Financing Cash Flow	$1K-99.6%	$356K-60.9%	$911K+9010.0%	$10K-98.5%	$657K-88.1%	$5.5M+183433.3%	-$3K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$0	N/A	N/A	N/A

RZLT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-42.4%+9.2pp	-51.6%-9.7pp	-41.9%-14.9pp	-26.9%+22.1pp	-49.1%+136.4pp	-185.4%
Current Ratio	14.37+1.0	13.39-6.8	20.18-41.6	61.78+40.4	21.34+18.1	3.26
Debt-to-Equity	0.08-0.0	0.10+0.0	0.07+0.0	0.02-0.5	0.54+0.5	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q2'25	Q1'25	Q3'25	Q2'24	Q1'24	Q3'24	Q2'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	17.8%	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	16.4%+32.9pp	-16.4%-5.0pp	-11.4%+8.5pp	-20.0%-5.9pp	-14.0%-1.6pp	-12.5%+7.0pp	-19.4%-5.8pp	-13.6%
Current Ratio	14.180.0	14.18-1.0	15.15+6.7	8.43-0.9	9.30-4.5	13.79+2.0	11.82-0.2	12.00
Debt-to-Equity	0.080.0	0.080.0	0.08-0.1	0.15+0.0	0.12+0.0	0.09-0.2	0.24+0.1	0.11
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Rigel Pharmaceuticals Inc RIGL

$645.3M

Kalvista Pharm KALV

$757.7M

Vir Biotechnology, Inc. VIR

$1.0B

Relay Therapeutics, Inc. RLAY

$1.6B

Theravance Bioph TBPH

$953.1M

Frequently Asked Questions

Is Rezolute Inc profitable?

No, Rezolute Inc (RZLT) reported a net income of -$74.4M in fiscal year 2025.

What is Rezolute Inc's earnings per share (EPS)?

Rezolute Inc (RZLT) reported diluted earnings per share of $-0.98 for fiscal year 2025. This represents a 26.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Rezolute Inc's EBITDA?

Rezolute Inc (RZLT) had EBITDA of -$79.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Rezolute Inc's operating cash flow?

Rezolute Inc (RZLT) generated -$69.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rezolute Inc's total assets?

Rezolute Inc (RZLT) had $175.5M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Rezolute Inc spend on research and development?

Rezolute Inc (RZLT) invested $61.5M in research and development during fiscal year 2025.

How many shares does Rezolute Inc have outstanding?

Rezolute Inc (RZLT) had 87M shares outstanding as of fiscal year 2025.

What is Rezolute Inc's current ratio?

Rezolute Inc (RZLT) had a current ratio of 14.37 as of fiscal year 2025, which is generally considered healthy.

What is Rezolute Inc's debt-to-equity ratio?

Rezolute Inc (RZLT) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rezolute Inc's return on assets (ROA)?

Rezolute Inc (RZLT) had a return on assets of -42.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rezolute Inc's cash runway?

Based on fiscal year 2025 data, Rezolute Inc (RZLT) had $94.1M in cash against an annual operating cash burn of $69.1M. This gives an estimated cash runway of approximately 16 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rezolute Inc's Piotroski F-Score?

Rezolute Inc (RZLT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rezolute Inc's earnings high quality?

Rezolute Inc (RZLT) has an earnings quality ratio of 0.93x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.